TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 6574611
Drug: Fortnightly sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fortnightly sodium fluoride rinsing and topical painting with ferric aluminum fluoride solution
Study: 6574611
Drug: Fortnightly sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fortnightly sodium fluoride rinsing and topical painting with neutral 0.2% sodium fluoride solution
Study: 19249429
Drug: clopidogrel 600
Approvals — FDA: no, EMA: no, PMDA: no
Description: clopidogrel 600 mg loading dose (LD)/75 mg maintenance dose (MD)
Study: 19249429
Drug: prasugrel 60
Approvals — FDA: no, EMA: no, PMDA: no
Description: prasugrel 60 mg LD/10 mg MD
Study: 15097437
Drug: Glutamine supplementation
Normalized name: Glutamine
DrugBank: L-Glutamine (DB00130)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Glutamine supplementation (0.3 g/kg/day for 7 days)
Study: 9489975
Drug: Urokinase (192
Approvals — FDA: no, EMA: no, PMDA: no
Description: Urokinase (192 U/ml, 1920 U/ml, 19,200 U/ml)
Study: 9489975
Drug: Tissue-type plasminogen
Normalized name: Tissue-type plasminogen activator
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tissue-type plasminogen activator (120 U/ml, 1200 U/ml, 12,000 U/ml)
Study: 9489975
Drug: Acetylsalicylic acid
Normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acetylsalicylic acid (160 mg/day)
Study: 9489975
Drug: Acetylsalicylic acid
Normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acetylsalicylic acid (660 mg/day)
Study: 7838915
Drug: d-amphetamine (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: d-amphetamine (15 mg) with vigilance activity
Study: 7838915
Drug: triazolam (0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: triazolam (0.25 mg) with relaxation activity
Study: 7838915
Drug: d-amphetamine (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: d-amphetamine (15 mg) with relaxation activity
Study: 7838915
Drug: triazolam (0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: triazolam (0.25 mg) with vigilance activity
Study: 3169214
Drug: Budesonide (high
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide (high dose, 1,000 and 1,200 micrograms per day)
Study: 3169214
Drug: Beclomethasone (high
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beclomethasone (high dose, 1,000 and 1,200 micrograms per day)
Study: 12207833
Drug: Folic acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Folic acid supplement
Study: 30762945
Drug: Noradrenaline infusion
Normalized name: noradrenaline hydrochloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: Noradrenaline infusion (median dose after 50 min 0.09 (range 0-0.26) μg kg-1 min-1)
Study: 30762945
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (standard care, NA administered only if MAP decreased below 60 mmHg)
Study: 23600548
Drug: 300IR 5-grass
Normalized name: Buffalo grass
DrugBank: Anthoxanthum odoratum (DB14163)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300IR 5-grass pollen sublingual tablet
Study: 20040526
Drug: Bosentan 62.5
Normalized name: bosentan 62.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bosentan 62.5 mg twice daily for 4 weeks, followed by 125 mg twice daily for 12 weeks
Study: 11901542
Drug: Peptide vaccines
Normalized name: peptide-T
DrugBank: Peptide-T (DB19279)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peptide vaccines derived from tumor antigens
Study: 10352750
Drug: Octreotide treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Octreotide treatment (daily dosage of 470 +/- 160 micrograms for 16.5 +/- 10 weeks)
Study: 10352750
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no Octreotide treatment)
Study: 8619354
Drug: Iobitridol 300
Normalized name: iobitridol 300 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iobitridol 300 mg I/ml
Study: 8619354
Drug: Iopromide 300
Normalized name: IOPROMIDE 300mgI/ml INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iopromide 300 mg I/ml
Study: 1953212
Drug: Pravastatin 40
Normalized name: pravastatin 40 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pravastatin 40 mg once daily at bedtime (n = 15)
Study: 1953212
Drug: Probucol 500
Normalized name: probucol 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probucol 500 mg twice daily (n = 11)
Study: 30186865
Drug: Ultrasonic implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasonic implant site preparation (UISP)
Study: 27278250
Drug: Mentalization-based treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mentalization-based treatment for psychotic disorders (18 months of therapy including 60 hours of group therapy and 15 hours of individual therapy)
Study: 24488700
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of neuroendocrine factors
Study: 19453582
Drug: Propofol 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol 0.5 mg.kg(‐1) + fentanyl 1 microg.kg(‐1) + ketamine 0.5 mg.kg(‐1)
Study: 19453582
Drug: Propofol 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol 0.5 mg.kg(‐1) + fentanyl 1 microg.kg(‐1) + same volume of %0.9 NaCl
Study: 15265969
Drug: High-dose chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose chemotherapy (four cycles of doxorubicin 75 mg/m2, followed by a single cycle of intermediate-dose cyclophosphamide 4000 mg/m2 supported by filgrastim 300 microg/day for up to 10 days, followed by high-dose cyclophosphamide 6000 mg/m2 and thiotepa 800 mg/m2)
Study: 15265969
Drug: Conventional chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional chemotherapy (four cycles of doxorubicin 75 mg/m2 followed by eight cycles of CMF: cyclophosphamide 600 mg/m2, methotrexate 50 mg/m2, and 5-fluorouracil 600 mg/m2)
Study: 2486586
Drug: Standard morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard morphine parenteral analgesia (Group 1)
Study: 1086422
Drug: Leucovorin-tablets
Normalized name: leucovorin Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Leucovorin-tablets
Study: 30526692
Drug: 35 µg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 35 µg vitamin D3/d
Study: 30526692
Drug: >85 µg
Approvals — FDA: no, EMA: no, PMDA: no
Description: >85 µg vitamin D3/d
Study: 30526692
Drug: 60 µg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 µg vitamin D3/d
Study: 30526692
Drug: 85 µg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 85 µg vitamin D3/d
Study: 23848107
Drug: Folic acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Folic acid supplementation (10 mg/day for 6 months)
Study: 8498867
Drug: Surgical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical treatment of varicocele (26 patients)
Study: 8498867
Drug: No therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: No therapy (41 patients)
Study: 8498867
Drug: All treatments
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All treatments (surgical, sclerosation, embolization)
Study: 27250601
Drug: 4 l
Normalized name: PEG-4 laurate
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 l polyethylene glycol (PEG) in a single dose
Study: 27250601
Drug: 4 l
Normalized name: PEG-4 laurate
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 l polyethylene glycol (PEG) split into 3 + 1 l
Study: 27250601
Drug: PEG +
Normalized name: Polyethylene glycol
DrugBank: Polyethylene glycol (DB09287)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PEG + ascorbic acid (PEGA) split into 1 + 1 l or 2 l
Study: 19322744
Drug: rosiglitazone 4
Normalized name: rosiglitazone 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: rosiglitazone 4 mg/day (n=23)
Study: 12620950
Drug: Continuous intra‐articular
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous intra‐articular infusion with 0.2% ropivacaine at 10 mL/hr for 48 hours
Study: 12620950
Drug: Continuous interscalene
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous interscalene block with 0.2% ropivacaine at 10 mL/hr for 48 hours
Study: 10946875
Drug: High serum
Approvals — FDA: no, EMA: no, PMDA: no
Description: High serum levels of insulin-like growth factor I (IGF-I)
Study: 10946875
Drug: Insulin-like growth
Normalized name: Insulin-like growth factor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin-like growth factor binding protein-3 (IGFBP-3)
Study: 8817135
Drug: Propranolol (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (10 mg every 6 hours postoperatively)
Study: 8817135
Drug: Diltiazem (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diltiazem (0.1 mg/kg per hour i.v.)
Study: 1486965
Drug: Slow-release theophylline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Slow-release theophylline and ketotifen (TK; T 300 mg+K 1 mg b.i.d.)
Study: 6363488
Drug: Atropine 2.08
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atropine 2.08 mg
Study: 3764397
Drug: Midazolam (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam (5 mg i.m.)
Study: 23706700
Drug: Macular leakage
Approvals — FDA: no, EMA: no, PMDA: no
Description: Macular leakage (ML) presence
Study: 20939644
Drug: Alcohol dose
Normalized name: Alcohol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alcohol dose of .100%
Study: 20939644
Drug: Alcohol dose
Normalized name: Alcohol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alcohol dose of .075%
Study: 20939644
Drug: Alcohol dose
Normalized name: Alcohol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alcohol dose of .050%
Study: 20939644
Drug: Alcohol dose
Normalized name: Alcohol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alcohol dose of .000%
Study: 16790517
Drug: Paclitaxel 175
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel 175 mg/m² on day 1 and gemcitabine 1000 mg/m² on days 1 and 8 every 3 weeks (group A)
Study: 16790517
Drug: Paclitaxel and
Normalized name: paclitaxel and encequidar
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paclitaxel and pegylated liposomal doxorubicin 40 mg/m² on day 1 every 4 weeks (group B)
Study: 15035763
Drug: Albuterol by
Normalized name: Albuterol
DrugBank: Albuterol (DB01001)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albuterol by nebulizer every 20 minutes up to 2 hours
Study: 15035763
Drug: Metered-dose inhaler
Normalized name: Metered Dose Inhaler
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metered-dose inhaler with spacer every 20 minutes up to 2 hours
Study: 11099870
Drug: Transdermal E(2)
Normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal E(2) and oral medroxyprogesterone acetate
Study: 11099870
Drug: Oral cyclic
Normalized name: cyclic AMP
DrugBank: Cyclic adenosine monophosphate (DB02527)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral cyclic association of oestradiol valerate and cyproterone acetate
Study: 18480626
Drug: 60 mg
Normalized name: opium 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg lidocaine suppository 2 h before biopsy
Study: 18480626
Drug: 120 mg
Normalized name: papain 120 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 120 mg lidocaine suppository 1 h before biopsy
Study: 18480626
Drug: 120 mg
Normalized name: papain 120 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 120 mg lidocaine suppository 2 h before biopsy
Study: 18480626
Drug: Periprostatic infiltration
Normalized name: Autologous tumor infiltrating lymphocytes
DrugBank: Lifileucel (DB17107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Periprostatic infiltration of 5 ml 2% lidocaine
Study: 12859158
Drug: Losartan (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Losartan (50 mg for 5 weeks, then 100 mg for 5 weeks)
Study: 12859158
Drug: Losartan (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Losartan (100 mg after 5 weeks)
Study: 8611830
Drug: Single daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single daily dose of aminoglycosides
Study: 8611830
Drug: Multiple daily
Normalized name: Multivitamin Oral Tablet [MULTIPLE DAILY W/BETA]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple daily doses of aminoglycosides
Study: 27718369
Drug: Ketamine (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine (single infusion of sub-anesthetic dose)
Study: 26202488
Drug: Denosumab treatment
Normalized name: Denosumab
DrugBank: Denosumab (DB06643)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Denosumab treatment for 8 years (long-term group)
Study: 26202488
Drug: Denosumab treatment
Normalized name: Denosumab
DrugBank: Denosumab (DB06643)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Denosumab treatment for 5 years (cross-over group)
Study: 26202488
Drug: Denosumab treatment
Normalized name: Denosumab
DrugBank: Denosumab (DB06643)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Denosumab treatment (both groups)
Study: 23176888
Drug: Early interventional
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early interventional treatment with mometasone furoate nasal spray (EIT group)
Study: 23176888
Drug: Postonset treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postonset treatment with mometasone furoate nasal spray (POT group)
Study: 25876224
Drug: Placebo treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo treatment (placebo group)
Study: 17080503
Drug: Method applied
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Method applied to bioequivalence study of two furosemide-containing formulations
Study: 11070330
Drug: LHRH (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: LHRH (400 microg acute administration)
Study: 9041232
Drug: Zileuton (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zileuton (600 mg qid)
Study: 9041232
Drug: Mesalazine (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mesalazine (400 mg qid)
Study: 8178840
Drug: Conjugated estrogens
Normalized name: Conjugated Estrogens
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conjugated estrogens (0.625 mg) with medroxyprogesterone acetate (2.5 mg daily)
Study: 8178840
Drug: Conjugated estrogens
Normalized name: Conjugated Estrogens
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conjugated estrogens (0.625 mg) with medroxyprogesterone acetate (5.0 mg daily)
Study: 8178840
Drug: Conjugated estrogens
Normalized name: Conjugated Estrogens
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conjugated estrogens (0.625 mg) with medroxyprogesterone acetate (5.0 mg for 14 days per 28-day cycle)
Study: 8178840
Drug: Conjugated estrogens
Normalized name: Conjugated Estrogens
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conjugated estrogens (0.625 mg) with medroxyprogesterone acetate (10.0 mg for 14 days per 28-day cycle)
Study: 8178840
Drug: Conjugated estrogens
Normalized name: Conjugated Estrogens
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conjugated estrogens (0.625 mg) alone
Study: 3228824
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg slow‐release isosorbide‐5‐mononitrate (ISMN SR) once daily
Study: 3228824
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg nifedipine SR twice daily
Study: 28780559
Drug: Low-energy total
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-energy total diet replacement programme (810 kcal/d) for 8 weeks, followed by gradual food reintroduction and weekly behavioural support for 24 weeks.
Study: 23810723
Drug: Budesonide (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide (3 mg twice or 3 times daily) with azathioprine (1-2 mg/kg/day)
Study: 23810723
Drug: Prednisone (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisone (40 mg/day tapered to 10 mg/day) with azathioprine (1-2 mg/kg/day)
Study: 23810723
Drug: Open-label budesonide
Normalized name: Budesonide
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Open-label budesonide treatment after 6 months
Study: 17519073
Drug: Triple-bead mixed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple-bead mixed amphetamine salts 37.5 mg
Study: 11464179
Drug: Micronized isotretinoin
Normalized name: Micronized ISOtretinoin 8 MG Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Micronized isotretinoin 0.4 mg/kg once daily without food (n = 300)
Study: 11464179
Drug: Standard isotretinoin
Normalized name: Isotretinoin
DrugBank: Isotretinoin (DB00982)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Standard isotretinoin 1.0 mg/kg per day in two divided doses with food (n = 300)
Study: 2266236
Drug: 0.1 M
Normalized name: biotin 0.1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1 M hydrochloric acid infusion
Study: 2266236
Drug: 1 M
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 M sodium bicarbonate infusion
Study: 27883269
Drug: Standard six-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard six-dose AL treatment with milk (A)
Study: 27883269
Drug: Two tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two tablets of AL
Study: 27883269
Drug: One tablet
Normalized name: Hydone Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: One tablet of AL
Study: 21901330
Drug: Dexmedetomidine (DEX)
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexmedetomidine (DEX) with a dose of 0.7 μg/kg/h after initial dose and effect-site concentration (ESC) of fentanyl of 2 ng/ml
Study: 21901330
Drug: Placebo (saline)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (saline) with ESC of fentanyl of 4 ng/ml
Study: 9735411
Drug: Pentoxifylline (PTX)
Normalized name: Pentoxifylline
DrugBank: Pentoxifylline (DB00806)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pentoxifylline (PTX) plus standard-dose external-beam whole-brain radiation treatment (WBRT)
Study: 26482278
Drug: Etirinotecan pegol
Normalized name: Etirinotecan pegol
DrugBank: Etirinotecan pegol (DB14951)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etirinotecan pegol (145 mg/m² as a 90-min intravenous infusion every 3 weeks)
Study: 21707533
Drug: Galantamine treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Galantamine treatment (subgroup analysis)
Study: 16929307
Drug: L-DOPA (3,4-dihydroxy-L-phenylalanine)
Normalized name: α-methyl-L-dopa
DrugBank: Levodopa (DB01235)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: L-DOPA (3,4-dihydroxy-L-phenylalanine)
Study: 11054514
Drug: Continuous hyperfractionated
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous hyperfractionated accelerated radiotherapy (V-CHART) delivering a total dose of 55.3 Gy in 33 fractions over 17 consecutive days
Study: 11054514
Drug: Continuous hyperfractionated
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous hyperfractionated accelerated radiotherapy with mitomycin C (V-CHART+MMC) with additional administration of 20 mg/m2 MMC on day 5 of treatment
Study: 9375429
Drug: Agents (prayers)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Agents (prayers)
Study: 9375429
Drug: Amount of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amount of prayer by agents
Study: 23206974
Drug: Booster dose
Normalized name: SARS-COV-2 (COVID-19) Vaccine, mRNA (Moderna) 50 MCG/0.5 ML Intramuscular Suspension [MODERNA COVID-19 VACCINE BOOSTER DOSE]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Booster dose administered 5 years post-vaccination
Study: 23206974
Drug: Booster dose
Normalized name: SARS-COV-2 (COVID-19) Vaccine, mRNA (Moderna) 50 MCG/0.5 ML Intramuscular Suspension [MODERNA COVID-19 VACCINE BOOSTER DOSE]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Booster dose administered 10 years post-vaccination
Study: 23206974
Drug: Booster dose
Normalized name: SARS-COV-2 (COVID-19) Vaccine, mRNA (Moderna) 50 MCG/0.5 ML Intramuscular Suspension [MODERNA COVID-19 VACCINE BOOSTER DOSE]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Booster dose administered 15 years post-vaccination
Study: 23206974
Drug: No booster
Approvals — FDA: no, EMA: no, PMDA: no
Description: No booster dose (5, 10, or 15 years post-vaccination)
Study: 21435876
Drug: 450 mg
Normalized name: aspirin 450 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 450 mg idebenone (Catena®)
Study: 18491311
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil (3.5 g daily)
Study: 18491311
Drug: High oleic
Normalized name: High Oleic Sunflower Oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: High oleic sunflower oil (3.5 g daily)
Study: 11213546
Drug: Fentanyl (2.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl (2.0 micrograms/kg) and atropine (0.01 mg/kg) as premedication
Study: 11213546
Drug: Remifentanil (0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil (0.2 microgram/kg/min) and atropine (0.01 mg/kg) as infusion
Study: 3881294
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg Ethinylestradiol (EE) for 5 consecutive days
Study: 3881294
Drug: 200 micrograms
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 micrograms Ethinylestradiol (EE) and 2 mg dl‐norgestrel (NG)
Study: 29419896
Drug: Excimer lamp
Approvals — FDA: no, EMA: no, PMDA: no
Description: Excimer lamp (twice weekly)
Study: 29419896
Drug: Calcipotriol-clobetasol combination
Normalized name: calcipotriol, combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcipotriol-clobetasol combination (once daily)
Study: 29419896
Drug: Calcipotriol-clobetasol combination
Normalized name: calcipotriol, combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcipotriol-clobetasol combination
Study: 27563091
Drug: Screening mechanism
Normalized name: SUN PROTECTANTS/SCREENS,TOPICAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Screening mechanism combining free provision of chlorine solution with household vouchers that need to be redeemed monthly.
Study: 24858151
Drug: Single visit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single visit root canal treatment
Study: 24858151
Drug: Multi visit
Normalized name: Parasedge Multi
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multi visit root canal treatment
Study: 20566266
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of pre-notification and follow-up
Study: 18036451
Drug: Sildenafil 50
Normalized name: sildenafil 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sildenafil 50 mg twice per day
Study: 15826716
Drug: Lactitol 60
Normalized name: Lactitol
DrugBank: Lactitol (DB12942)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lactitol 60 g/day